Motor effects of the partial dopamine agonist (−)‐3‐(3‐hydroxyphenyl)‐N‐n‐propylpiperidine (preclamol) in Parkinson's disease

L. Verhagen Metman, V. H. Sethy, J. R. Roberts, D. Bravi, J. I. Hoff, M. M. Mouradian, T. N. Chase*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


The motor effects of the partial dopamine agonist (–)‐3‐(3‐hydroxyphenyl)‐N‐n‐propylpiperidine [(–)‐3‐PPP, preclamol] were evaluated in nine patients with Parkinson's disease using a double‐blind, placebocontrolled design. (–)‐3‐PPP monotherapy had an antiparkinsonian effect in five of nine patients at a mean dose of 37 ± 10 mg intramuscularly. The co‐administration of (–)‐3‐PPP and a mildly dyskinetic dose of levodopa, infused intravenously at steady‐state, resulted in complete suppression of dyskinesias and reemergence of parkinsonian signs in two of seven patients. These dopamine antagonist effects of (–)‐3‐PPP occurred at relatively low (2.5 and 5 mg) doses. Our results suggest that partial dopamine agonists can exert agonist or antagonist activity in parkinsonian patients depending on concurrent dopaminergic tone. Although this dual action of (–)‐3‐PPP and other partial agonists could be therapeutically important on theoretical grounds, the small number of patients manifesting a clinically significant response and the frequently inconsistent effects could indicate that this class of agents may have relatively limited clinical utility.

Original languageEnglish (US)
Pages (from-to)577-581
Number of pages5
JournalMovement Disorders
Issue number5
StatePublished - 1994


  • (‐)‐3–PPP
  • Dyskinesias
  • Parkinson's disease
  • Partial dopamine agonist
  • Preclamol

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Motor effects of the partial dopamine agonist (−)‐3‐(3‐hydroxyphenyl)‐N‐n‐propylpiperidine (preclamol) in Parkinson's disease'. Together they form a unique fingerprint.

Cite this